There is increasing experimental and clinical evidence that a number of cytokines play a major role in the response to injury and infection and in the development of organ damage in critically ill patients. Tumour necrosis factor (TNF) is now proposed to be a key mediator of organ injury during sepsis. It is elevated early in the course of septic shock and high levels correlate with unfavourable outcome. In animals it can produce the effects of endotoxin. The prophylactic administration of anti-TNF antisera protects mice and rabbits from lethal effects of lipopolysaccharide. Interleukin-1 (IL-1) is an endogenous pyrogen which induces leukocytosis and muscle catabolism. It causes hypotension and tachycardia by reducing smooth muscle con tractility. IL-1 receptor blockers have been shown to diminish mortality in experimental endotoxic shock. Interleukin-6 (IL-6) is a pyrogen and lymphocyte activator. It is the major stimulus to acute phase protein production by the liver. A recently described neutrophil-activating peptide may be involved in the pathogenesis of ARDS. High blood levels of IL-8 have been found in patients with septic shock. Platelet-derived growth factor (PDGF) has been shown to stimulate TNF production, leukocyte chemotaxis and pulmonary vasoconstriction in response to endotoxin. Other cytokines and growth factors have not yet been studied in critical illness. The cytokine network can be either protective or damaging. Its activation during critical illness triggers complex and still poorly understood interactions. A better comprehension of its role in protection from infection and in the pathogenesis of multiple organ failure may allow therapeutic manipulations aimed at minimising adverse effects while retaining immunological protection.
One of the fastest growing areas of immunology is that of cytokine biology. The extraordinary number of publications found in the medical literature on this subject more than confirms this. Because of the major role that cytokines clearly play in the pathophysiology of inflammation, attention has inevitably focussed on their significance in critical illness, sepsis and multiple organ failure. Thus, the intensivist should become familiar with what is known of cytokine biology and its potential clinical signficance. This article seeks to offer a review of the area with particular emphasis on its relation to critical care medicine. GENERAL CONCEPTS Cytokine is a term used for protein cell regulators produced by various effector cells. These proteins act as intercellular signals and have the ability to modify the behaviour of closely adjacent cells. I -3
They are usually pf low molecular weight ( < 80 KDa) and are extremely potent (acting at pi co molar concentrations). They are involved in both immunity and inflammation and regulate the amplitude and duration of the inflammatory response 2 by binding to high affinity specific cell surface receptors and triggering changes in the pattern of mRN A and protein synthesis. Cytokines as a whole have multiple overlapping cell regulatory actions and the response of a cell to a given cytokine depends on the cytokine's local concentration, the cell type and the presence of other cytokines to which it is being concomitantly exposed. In addition to these paracrive functions, 3, 4 cytokines have also been documented to function in an autocrine way (i.e. the originating cell is the target of the cytokine). 3,5 These interactions are further modulated by changes in receptor density and by solubilisation of specific receptors 6 which may then act as inhibitors of cytokine function. 6 The growing awareness of these complex interactions between cytokines, effector cells, target cells and receptors has led to the concept of an intricate network of polypeptides maintaining or seeking to maintain homeostasis, rather than individual cytokines being responsible for particular biological events. This concept, gained from in vitro research, makes the interpretation of in vivo data very difficult indeed. The measurement of cytokine concentrations in body fluids in vivo mayor may not reflect anticipated intercellular interactions and certainly cannot take into account what effect other cytokines may be having on various effector or target cells at the very same time. While a markedly elevated concentration of a cytokine in a body fluid is most likely to reflect high concentrations in the biological microenvironment, it may also reflect a deficiency of inhibitors; equally, the inability to measure the presence of a cytokine in blood, CSF or synovial fluid does not necessarily imply a lack of biological activity at a cellular level. Thus, although many cytokines are detectable in blood or other fluids by means of bioassays,7·14 ELISAs or RIAs, the interpretation of what we measure is, at best, controversial. These caveats should, therefore, be kept in mind when reviewing the data now available on each individual cytokine.
THE INDIVIDUAL CYTOKINES

Tumour necrosis factor-alpha
Tumour necrosis factor-alpha (TNF) is a proinflammatory polypeptide produced primarily by macrophages/monocytes in response to endotoxin exposure. It circulates as a dimer or a trimer of 17 KDa subunits and is distinct from other cytokines in being strikingly cytotoxic. In a sense, in fact, TNF belies the fundamental precept of cytokine biology which states that cytokines act locally only. TNF was initially known as Cachectin because of its ability to cause lypolysis and glycogenolysis in adipocytes and skeletal myocytes and to induce anorexia, weight loss and anaemia if given in sublethal doses to animals. 15 ,16 Since its initial description and characterisation, a number of in vitro studies have established the multiple effects of TNF. Such effects include necrosis of tumour cells,17,18 increased nutrophil adherence to endothelium I 9-2 I and activation,22.23 stimulation of new vessel formation,24 induction of pyrogens,25 procoagulants 26 -31 and inhibitors of fibrinolysis,32-34 as well as degradaton of thrombomodu-lin. 35 ,36 TNF induces endothelial proliferation 37 and the production of interleukin-6,38 interleukin-8 39 and prostaglandin E2. 40 It inhibits the  expression of surfactant protein,41 induces IL-l  production, stimulates endothelial cells to produce  Class I MHC molecules 42 and leads to free radical  production. 42 TNF activates macrophages, induces an antiviral state,2.43 stimulates eosinophil activity and osteoclast bone resorption. 43 Metabolically, TNF induces not only adipocyte function inhibition, but also a state of apparent post receptor insulin resistance. 44 These multiple pro-inflammatory, cytocidal and metabolic effects shown in vitro are reflected in a plethora of in vivo effects which have established a very strong link between TNF and inflammatory disease, cachexia, infection, sepsis, septic shock and organ damage. A number of recent reviews have, in fact, focussed on these aspects. 45-60 A great deal of information has come from animal models of infection, malignancy and overwhelming sepsis in which multiple inflammatory stimuli have been shown to induce TNF production (viruses, C5a, fungal, bacterial or parasitic antigens, IL-I, TNF itself and, very potently, lipopolysaccharide).61. 55. 62 Steroids inhibit its biosynthesis 64 and gamma interferon has a permissive effect on it. 63 . 64 The in vivo effects on TNF release include fever, lactic acidosis, stress hormone release, hyperglycemia, diuresis,65 capillary leakiness and finally, all the hemodynamic features of septic shock. [66] [67] [68] [69] In fact, TNF injection alone can reproduce all the features of lethal bacteremic shock 7o -75 and both passive and active immunisation against TNF have a major protective effect against lipopolysaccharide-induced septic shock. 7 6-79 Furthermore, elevation ofTNF typically occurs early in experimental sepsis or major inflammatory injury and the magnitude of its response appears to correlate with prognosis and organ damage. 69.80-87 These lines of evidence linking TNF to organ injury during sepsis are further supported by experimental work showing that TNF antagonists have a beneficial effect in endotoxin-induced septic shock,88-90 although not all effects of endotoxin shock appear mediated by TNF. 91 There are now numerous reports of elevated circulating levels of TNF in a number of inflammatory and infectious conditions in humans92-104 that further the case of a pathogenic connection between excessive TNF production and organ damage. This is particularly true in septic shock and after endotoxin administration I06 -116 and in malignancy where cachexia develops when TNF is produced chronically at relatively low levels.117.118 Volunteer studies confirm its ability to induce the activation of intravascular In humans I. Elevated blood levels in septic shock, cardiac cachexia, meningitis and fulminant hepatic failure 2. Elevated levels in bronchoalveolar lavage in ARDS 3. Elevated blood levels after endotoxin 4. Activates coagulation in volunteers 5. High blood levels in infectious purpura 6. Very high blood levels associated with poor prognosis in sepsis 7. Implicated in pathogenesis of graft versus host disease, Kawasaki disease, multiple sclerosis and rheumatoid arthritis 8. Anorexia and negative nitrogen balance 9. Induces fever, myalgias, headache and rigors in volunteers coagulation, ll9 fever and rigors120 and the typical metabolic changesl21-125 of sepsis. Any association with the pathogenesis of ARDS is still in doubt. [126] [127] [128] [129] More recently, preliminary reports on the use of antibodies against TNF in the management of sepsis and rejection have shown some promise. 130,131 While TNF excess may be deleterious to the organism, there is also evidence that TNF does have a protective effect in some bacterial infections. 132 This suggests that its effects are most likely dependent on its modulation and magnitude of secretion. It is clear that TNF is a complex molecule with multiple effects which will require much more research to unravel. Its connection with the pathogenesis of septic shock, however, is already leading to attempts to modulate its circulating levels even before a full understanding of its biological significance is at hand. 130 ,133 The multiple findings of in vitro, animal and human in vivo studies regarding TNF are summarised in Table 1 ,
In vitro
Interleukin-l (lL-l) was the first interleukin to be described and it has been extensively studied since its first description in 1972. 134 ,135 Its biology has been recently reviewed,136,137 It exists as two species, IL-1 alpha and IL-1 beta, with similar activities and a molecular weight in the range of 17 KDa. It is principally produced by macophages but virtually every nucleated cell can produce it in response to injury, IL-1 has a broad spectrum of target cells and actions. In vitro, it is a growth factor for certain T -helper cells, B cells and for haemopoietic cell lines. IL-1 has a proinflammatory effect on fibroblasts, synovial cells, chondrocytes, endothelial cells, hepatocytes and osteoclasts. It can induce prostaglandin production and the secretion of inflammatory proteins as well as the secretion of other pro-inflammatory interleukins. 138 It is a powerful pyrogen 132,139,140 and inducer of endothelial activation and expression of leukocyte adhesion molecules. 141 It also affects the metabolic function of hepatocytes 58 ,142 glucose homeostasis 143 and amino acid utilisation by muscle. 144 IL-1 induced changes in vascular permeability may be important in the development of ARDS and distributive shock. [145] [146] In vivo in experimental animals, it can have beneficial effects such as increased resistance to bacterial infections or radio-protection 147-148 but when given in higher amounts, it exerts deleterious effects such as the induction of hypotension, a shock-like state,149 granulocytopenia and pulmonary leukostasis. 150 In conjunction with TNF, it induces the synergistic development of a Shwartzman-like reaction 151 which is aggravated Nonetheless, it is probable that attempts to modulate its response to sepsis will soon be undertaken.
Anaesthesia and Intensive Care, Vol. 20, No. 3, August, 1992 Interleukin-2 Interleukin-2 (IL-2) is a potent T cell growth factor which is secreted and synthesised by T lymphocytes after their activation by antigen, 155.156 It is a glycoprotein of 15.5 KDa which binds to a specific receptor present on polyclonally activated T cells inducing T cell cytotoxicity and natural killer cell activity. 157 IL-2 is of vital importance to the activation of the T cell arm of the immune system and antibodies to its receptor show promise as immunosuppressive agents. 155 IL-2 is being used as part of an approach to the immunological management of cancer. 158-160 Its ability to induce capillary leakiness in vivo is well known. A preliminary report 116 did not show a measurable increase in its blood levels during septic shock in man and another 167 showed diminished IL-2 activity in the critically ill in association with measurable elevations in IL-2 receptors, TNF and prostaglandin E2. Thus, at present, the changes in IL-2 production and activity during septic shock or critical illness are less understood than those of IL-I and TNF.
Interleukin-3
Interleukin-3 (IL-3) is a T-Iymphocyte-derived glycoprotein of28 KDa 156 produced by activated T cells. 162 It is involved in regulating the growth and differentiation of hemopoietic progenitor cells. 163 It leads to the production of major cell types in the bone marrow, including mast cells. Its action is synergistic with that of interleukin-6 164 and erythropoietin. Currently, it is believed that IL-3 production during immune reactions may serve to recruit additional haemopoietic cells to sustain or amplify these responses. 156 There is no data on its role in critical illness.
Interleukin-4
Interleukin-4 (lL-4) is another immunerecognition induced cytokine which is made principally by T-helper cells. It is a glycoprotein with an approximate molecular weight of 19 KDa 165 which stimulates Band T cell growth,166-168.178 haemopoiesis,169 intrathymic T cell development 170 and function.171 It also possesses other interesting properties that may have significance in the setting of systemic infection, particularly with parasites. It is principally responsible for the production ofIgE in response to appropriate stimuli. l72 Monoclonal anti IL-4 antibodies will block the IgE response to helminthic infection. IL-4 has also been shown to have an inhibitory effect on some B cell responses and proliferation induced by IL_2. 173 -175 Thus, once again, the overall effects depend on the balance of stimuli within the network. Furthermore, IL-4 has been demonstrated to have some immunosuppressive properties such as the ability to suppress macrophage induced TNF, IL-I and IgE production. 176 It can block the immune response against Leishmania major in experimental animals 177, I 78 leading to a progressive disease. This can be reversed by anti-IL-4 antibody. A similar situation can be seen in experimental Schistosomiasis.1 65 No information is available concerning IL-4 in critical illness.
Interleukin-5
Interleukin-5 (IL-5) is a T cell derived glycoprotein of 45 KDa in molecular weight which induces B cells to differentiate into immunoglobulin-secreting cells following antigenic stimulationl79-181 and which is capable of inducing the growth of bone marrow cells already committed to the eosinophilic lineage. 182,183 This property has led to the term of eosinophil differentiation factor being used. Despite its probable involvement in antibody production, there is at present no information on the possible role of IL-5 in human disease.
Interleukin-6
Interleukin-6 (lL-6) is a glycoprotein of molecular weight ranging between 22 and 29 KDa which can be produced by T and B cells, macrophages, endothelial cells, fibroblasts, mast cells and keratinocytes. 6 ,184-186 Its production is induced by viruses, lipopolysaccharide, IL-I, TNF, interferon gamma and platelet-derived growth factor. 187 Its biological activities are many and of major significance to human disease. IL-6 is a growth factor for plasmacytomas and an inducer of B cell transformation into plasma cells 187 ,188 as well as an overall B cell activator. These properties have led to the speculation that it may be involved in B lymphocyte dyscrasias in humans. 189 IL-6 can activate T cells in the early phase of growth, particularly in association with IL_1190,191 and induce thrombocytopoiesis. 192 Finally, and of more immediate relevance to the clinician, IL-6 is now believed to be the main glycoprotein responsible for inducing the synthesis of acute proteins. [193] [194] [195] This property has been shown in vitro and in vivo, is enhanced by steroids and is associated with pyrexia 196-203 as well as increased corticosteroid production. 204 Numerous observations indicate that IL-6levels in body fluids increase rapidly after infection. [205] [206] [207] After lipopolysaccharide injection, they rise at 30 minutes and peak at two hours.208 An early increase is also observed in CSF during meningitis 205 and in serum after severe burns 203 or sepsis. 187 With respect to septic shock, however, the relative lack of toxicity of IL-6 in experimental animals would argue against a major causative role despite its high serum levels. Conceivably, the high titres of IL-6 found in acute infection or inflammation result from complex amplification Table 3 .)
In vitro
I nterleukin-7
Interleukin-7 (IL-7) is a recently discovered 25 KDa protein which acts as a stromal cell factor capable of inducing the growth and proliferation of B cell precursors. 2IO Both pre-Band pro-B cells (B cell precursors at different stages of development) response to it. [211] [212] Recently, it has been documented to also induce the proliferation of immature thymocytes. There is no knowledge of the role if IL-7 in human disease.
I nterleukin-8
Interleukin-8 (lL-8) is a polypeptide of 72 amino acids produced by a variety of cells (alveolar macrophages, epithelial cells, fib rob lasts and hepatocytes) in [esponse to stimulation by IL-I, TNF and lipopolysaccharide. It powerfully induces neutrophil chemotaxis and enzyme release.215 IL-8 acts via a selective receptor and does not stimulate monocytes. There is, however, evidence for chemotactic activity on lymphocytes and, partly, on eosinophils. Intradermal IL-8 is probably involved in the pathogenesis of rheumatoid arthritis. 216 Its production is increased in the lung following hypoxia-hyperoxia 217 and in the setting of neutrophilic alveolitis. 218 IL-8 has been shown to prime human neutrophils for enhanced superoxide production 215 and its levels rise markedly in humans after the intravenous administration of small doses of endotoxin. 218 Finally, high concentrations have been recently demonstrated in septic shock patients. 219 Survivors appeared to have higher mean levels of IL-8, suggesting a possible protective role for this cytokine in septic shock. The involvement of IL-8 in neutrophil recruitment following sepsis or TNF stimulation makes it a likely participant in the development of ARDS, but at this stage there is no study in humans to support such speculations.
Interleukin-9 and Interleukin-lO
These two cytokines have been isolated only very recently.214 Interleukin-9 (lL-9) is a growth factor for lymphoid and myeloid lineages, while Interleukin-IO (IL-IO) is active on T cells, mast cells and B cells. There is no information on the role of these cytokines in human disease.
Monocyte chemoattractant protein-I (Mep-I)
Mep-I is a 76 amino acid polypeptide which has been recently characterised and which is capable of inducing chemotaxis and activation of human monocytes. 220 It can be produced by lymphocytes, fibroblasts or monocytes stimulated with TNF, IL-I, platelet derived growth factor or lipopolysaccharide and may be an important mediator in the pathogenesis of human disease. At present, no studies have yet taken place to address this issue.
The interJerons (IFN)
The human interferons are a multigene famlily of proteins which can be divided into three main types (IFN alpha, IFN beta, IFN gamma). They are of molecular weights of 17 to 25 KDa221.224 and can be FLOWCHART induced by various stimuli (viruses, bacteria, antigens, TNF, IL-I, IL-2) in all cells but particularly in monocytes, fibroblasts and epithelial cells. They enhance the immune response by inducing major histocompatibility complex class I and 11 proteins,223 the expression of Fc receptors and cytokine receptors. They block intracellular viral replication and can also inhibit the transcription of oncogenes. While IFN-alpha has now been used extensively in the management of various malignancies (hairy-cell leukemia, chronic myeloid leukemia, multiple myeloma, lymphoma and solid tumours) with good effect, it has only been more recently that it has evolved as an accepted treatment for chronic active hepatitis of viral aetiology.225-227 From the critical care physician's point of view, however, IFN-gamma appears of greater interest as it is a much more potent immunomodulator and interacts more closely with other cytokines. 223 It has been shown to be protective in leprosy,228 to aid in vaccination against malaria,229 to partially correct the phagocytic defect of chronic granulomatous disease 230 and to increase survival and reduce sepsis in mice with simulated surgical wound infection. 231 As a result of these preclinical studies, a multicentre trial of short-term prophylactic IFNgamma in patients with acute trauma is under way. KDa. Despite its name, it can be produced by monocytes, fibroblasts and endothelial cells under a variety of stimuli. 35 ,224,233 It appears to be an important growth factor 235 acting on a broad spectrum of cells. PDGF is likely to be important in the generation of granulation tissue during wound repair, in inflammatory reactions associated with fibroproliferative response and in atherosclerosis. In this regard it has been implicated in the development of pulmonary fibrosis, where alveolar macrophages have been shown to express PDGF in greater amounts than in control patients, in the pathogenesis of scleroderma skin changes and in the synovial cell proliferation of rheumatoid arthritis. Finally, PDGF has also been shown to participate in the release of pro-inflammatory cytokines but its role in septic shock or severe infection has not yet been elucidated.
Transforming growth factors (TGF)
Transforming growth factors alpha and beta (TGF-alpha/TGF-beta) are distinct peptides with unique biological activities and separate receptor systems. 236 ,23? TGF-alpha is made by keratinocytes and macrophages and has been shown to be produced by cancer cells. It is a powerful growth factor and, in malignancy, it may function as an autocrine stimulator of growth. 23 ?
TGF-beta, instead, has recently been shown to play an important role in the modulation of the inflammatory response.238.240 A typical histological pattern of inflammation can be triggered by the subcutaneous injection of TGF-beta. TGF-beta is released by the alpha granules of aggregating platelets and is powerfully chemotactic for monocytes. Following chemotaxis, it activates them to produce IL-l, TNF, PDGF and, therefore, amplifies the phlogistic response. Furthermore, TGF-beta induces its own production in an auto cri ne fashion. 240 These pro-inflammatory actions are modulated and regulated by the need for TGF-beta to be cleaved before becoming an active cytokine and by the down-regulation of its receptors on the surface of macrophages. The other side of TGF-beta's action is directed to the inhibition ofB and T cell proliferation. This occurs at femtomolar concentrations 24o and makes this cytokine one of the most biologically potent lymphocyte suppressors known to man. Thus, the unique ability of TGF-beta to augment certain aspects of the immune response while dampening others suggests that this peptide may play an important immunoregulatory role in inflammatory states. Studies in disease models and human disease states have not yet been performed to elucidate the effect of these properties at a pathophysiological level in vivo.
The haemopoietic factors
These are a group of glycoproteins with high biological activity, capable of stimulating the formation of maturing colonies of these cells. Erythropoietin is one of these but it acts more like a hormone than a cytokine and will not be discussed here. IL-l, IL-3, IL-4, IL-5, IL-6 have already been discussed. A number of colony stimulating factors (CSFs) remain that are specific for a given lineage: granulocyte-macrophage CSF (GM-CSF), granulocyte CSF (G-CSF) and macrophage CSF (M-CSF). They are 18,20 and 50 KDa in molecular weight respectively,241 are specific for the cell lineage from which they derived their name and are produced by many cell types, including fibroblasts, macrophages, endothelial cells, T and B lymphocytes and some epithelial cells. 242 Their levels can increase up to 1000 times after inductive signals such as endotoxin or foreign antigens. CSFs not only act as mandatory proliferative stimuli for responding granulocytes and macrophages but lead to superoxide production,242 increased phagocytosis and the production of other cytokines 243 by both neutrophils and macrophages. These cytokines have already found a clinical niche for their use in bone marrow rescue following bone marrow transplantation where they have been shown to reduce the duration of chemotherapyassociated neutropenia. There has not yet been any study of their potential roles as adjuncts to antimicrobial therapy but it is likely that we will see an attempt to use them in overwhelming sepsisassociated neutropenia.
SUMMARY
The cytokine network, as briefly summarised in this article, is already known to be extraordinarily complex. Despite significant gaps in our understanding of its function and interactions, it is already abundantly clear that it provides one of the most exciting possibilities for the modulation, enhancement, and when necessary, downregulation of the inflammatory response to disease. It is not only important for the intensivist to be familiar with developments in this area but it is equally important that he or she should grasp the fundamental rules of this biological alphabet and thus avoid the oversimplifications that may accompany the future clinical use of these polypeptides and of their antagonists. 
